Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBITDA Margin: 2019-2025

Historic EBITDA Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -120.30%.

  • BridgeBio Pharma's EBITDA Margin rose 689837.00% to -120.30% in Q3 2025 from the same period last year, while for Sep 2025 it was -172.39%, marking a year-over-year increase of 7759.00%. This contributed to the annual value of -267.22% for FY2024, which is 626153.00% up from last year.
  • BridgeBio Pharma's EBITDA Margin amounted to -120.30% in Q3 2025, which was up 0.95% from -121.45% recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's EBITDA Margin ranged from a high of 19,953.49% in Q4 2021 and a low of -38,200.00% during Q3 2022.
  • For the 3-year period, BridgeBio Pharma's EBITDA Margin averaged around -4,465.75%, with its median value being -3,854.61% (2023).
  • Examining YoY changes over the last 5 years, BridgeBio Pharma's EBITDA Margin showed a top increase of 12,445,267bps in 2021 and a maximum decrease of 3,881,206bps in 2021.
  • Over the past 5 years, BridgeBio Pharma's EBITDA Margin (Quarterly) stood at 19,953.49% in 2021, then slumped by 2,686,430bps to -6,910.80% in 2022, then plummeted by 325,630bps to -10,167.11% in 2023, then spiked by 632,442bps to -3,842.69% in 2024, then spiked by 689,837bps to -120.30% in 2025.
  • Its EBITDA Margin was -120.30% in Q3 2025, compared to -121.45% in Q2 2025 and -89.49% in Q1 2025.